Table 3. Clinical and economic outcomes with navigation as part of a longitudinal screening program in a 10,000-person predominantly minority cohort: Base case.
| No Screening | FOBT, 40% uptake | Colonoscopy without Navigation, 40% uptake | FIT, 40% uptake | FOBT, 65% uptake | Colonoscopy with Navigation, 65% uptake | FIT, 65% uptake | |
|---|---|---|---|---|---|---|---|
| CRC cases per 10,000 persons | 580 | 470 | 410 | 435 | 401 | 304 | 345 |
| CRC stage | |||||||
| Localized | 40% | 46% | 42% | 45% | 51% | 45% | 51% |
| Regional | 37% | 35% | 37% | 35% | 32% | 36% | 32% |
| Distant | 23% | 20% | 21% | 20% | 17% | 19% | 18% |
| CRC deaths per 10,000 persons | 226 | 166 | 153 | 156 | 129 | 108 | 113 |
| QALYs/person | 19.2157 | 19.2423 | 19.2460 | 19.2465 | 19.2589 | 19.2649 | 19.2657 |
| Cost/person | $2,401 | $2,123 | $2,475 | $2,183 | $1,949 | $2,661 | $2,046 |
| ICER | |||||||
| No Screening | - | Dominates | $2,400 | Dominates | Dominates | $5,300 | Dominates |
| FOBT, 40% uptake | - | $95,400 | $14,200 | Dominates | $23,800 | Dominates | |
| Colonoscopy without Navigation | - | Dominates | Dominates | $9,800 | Dominates | ||
| FIT, 40% uptake | - | Dominates | $26,000 | Dominates | |||
| FOBT, 65% uptake | - | $118,700 | $14,200 | ||||
| Colonoscopy with Navigation | - | Dominates | |||||
CRC, colorectal cancer; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio; FOBT, fecal occult blood test; FIT, fecal immunochemical test.